We used CRISPR–Cas9 to generate HOXB8 progenitors with biallelic Tet2 mutations—the most common premalignant alteration in BPDCN—and then differentiated these cells into mature pDCs and cDCs (Extended Data Fig. 10f). This evidence concerns the gene TET2 and CD4+/CD56+ hematodermic neoplasm.